Hospital admissions in the last year of life of patients with heart failure.

IF 5.4 3区 材料科学 Q2 CHEMISTRY, PHYSICAL ACS Applied Energy Materials Pub Date : 2024-03-01 DOI:10.1093/ehjqcco/qcad047
Alexandra A I Abel, Nathan A Samuel, Joseph J Cuthbert, Oliver I Brown, Pierpaolo Pellicori, Syed Kazmi, John G F Cleland, Miriam J Johnson, Andrew L Clark
{"title":"Hospital admissions in the last year of life of patients with heart failure.","authors":"Alexandra A I Abel, Nathan A Samuel, Joseph J Cuthbert, Oliver I Brown, Pierpaolo Pellicori, Syed Kazmi, John G F Cleland, Miriam J Johnson, Andrew L Clark","doi":"10.1093/ehjqcco/qcad047","DOIUrl":null,"url":null,"abstract":"<p><strong>Aim: </strong>To explore the frequency, causes, and pattern of hospitalisation for patients with chronic heart failure (HF) in the 12 months preceding death. We also investigated cause of death.</p><p><strong>Methods: </strong>Patients referred to a secondary care HF clinic were routinely consented for follow-up between 2001 and 2020 and classified into three phenotypes: (i) HF with reduced ejection fraction (HFrEF), (ii) HF with preserved ejection fraction (HFpEF) with plasma N-terminal pro B-type natriuretic peptide (NT-proBNP) 125-399 ng L-1, and (iii) HFpEF with NT-proBNP ≥400 ng L-1. Hospital admissions in the last year of life were classified as: HF, other cardiovascular (CV), or non-cardiovascular (non-CV). The cause of death was systematically adjudicated.</p><p><strong>Results: </strong>A total of 4925 patients (38% women; median age at death 81 [75-87] years) had 9127 hospitalisations in the last year of life. The median number of hospitalisations was 2 (1-3) and total days spent in hospital was 12 (2-25). Out of the total, 83% of patients had ≥1 hospitalisation but only 20% had ≥1 HF hospitalisation; 24% had ≥1 CV hospitalisation; 70% had ≥1 non-CV hospitalisation. Heart failure hospitalisations were most common in patients with HFrEF, but in all groups, at least two thirds of admissions were for non-CV causes. There were 788 (16%) deaths due to progressive HF, of which 74% occurred in hospital.</p><p><strong>Conclusion: </strong>For patients with chronic HF in the last year of life, most hospitalisations were for non-CV causes regardless of HF phenotype. Most patients had no HF hospitalisations in their last year of life. Most deaths were from causes other than progressive HF.</p>","PeriodicalId":4,"journal":{"name":"ACS Applied Energy Materials","volume":null,"pages":null},"PeriodicalIF":5.4000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Energy Materials","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/ehjqcco/qcad047","RegionNum":3,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, PHYSICAL","Score":null,"Total":0}
引用次数: 0

Abstract

Aim: To explore the frequency, causes, and pattern of hospitalisation for patients with chronic heart failure (HF) in the 12 months preceding death. We also investigated cause of death.

Methods: Patients referred to a secondary care HF clinic were routinely consented for follow-up between 2001 and 2020 and classified into three phenotypes: (i) HF with reduced ejection fraction (HFrEF), (ii) HF with preserved ejection fraction (HFpEF) with plasma N-terminal pro B-type natriuretic peptide (NT-proBNP) 125-399 ng L-1, and (iii) HFpEF with NT-proBNP ≥400 ng L-1. Hospital admissions in the last year of life were classified as: HF, other cardiovascular (CV), or non-cardiovascular (non-CV). The cause of death was systematically adjudicated.

Results: A total of 4925 patients (38% women; median age at death 81 [75-87] years) had 9127 hospitalisations in the last year of life. The median number of hospitalisations was 2 (1-3) and total days spent in hospital was 12 (2-25). Out of the total, 83% of patients had ≥1 hospitalisation but only 20% had ≥1 HF hospitalisation; 24% had ≥1 CV hospitalisation; 70% had ≥1 non-CV hospitalisation. Heart failure hospitalisations were most common in patients with HFrEF, but in all groups, at least two thirds of admissions were for non-CV causes. There were 788 (16%) deaths due to progressive HF, of which 74% occurred in hospital.

Conclusion: For patients with chronic HF in the last year of life, most hospitalisations were for non-CV causes regardless of HF phenotype. Most patients had no HF hospitalisations in their last year of life. Most deaths were from causes other than progressive HF.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
心力衰竭患者生命最后一年的住院情况。
目的:探讨慢性心力衰竭(HF)患者在死亡前12个月内住院的频率、原因和模式。我们还调查了死亡原因:2001年至2020年期间,我们对转诊至二级医疗机构心力衰竭门诊的患者进行了常规随访,并将其分为三种类型:(i) 射血分数降低型心力衰竭(HFrEF);(ii) 射血分数保留型心力衰竭(HFpEF),血浆N-末端前B型利钠肽(NT-proBNP) 125-399 ng L-1;(iii) HFpEF,NT-proBNP≥400 ng L-1。生命最后一年的入院情况分为以下几类:HF、其他心血管(CV)或非心血管(non-CV)。对死亡原因进行系统判定:共有 4925 名患者(38% 为女性;死亡时的中位年龄为 81 [75-87] 岁)在生命的最后一年住院治疗 9127 次。住院次数中位数为 2 次(1-3 次),住院总天数为 12 天(2-25 天)。其中,83%的患者≥1次住院,但只有20%的患者≥1次心力衰竭住院;24%的患者≥1次心血管疾病住院;70%的患者≥1次非心血管疾病住院。HFrEF 患者中心力衰竭住院最为常见,但在所有组别中,至少有三分之二的患者因非冠心病原因住院。有788人(16%)死于进展性心房颤动,其中74%发生在医院:结论:对于生命最后一年的慢性心房颤动患者来说,无论心房颤动的表型如何,大多数住院治疗都是由于非冠状动脉疾病的原因。大多数患者在生命的最后一年没有因心房颤动住院。大多数患者死于进展性心房颤动以外的原因。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
ACS Applied Energy Materials
ACS Applied Energy Materials Materials Science-Materials Chemistry
CiteScore
10.30
自引率
6.20%
发文量
1368
期刊介绍: ACS Applied Energy Materials is an interdisciplinary journal publishing original research covering all aspects of materials, engineering, chemistry, physics and biology relevant to energy conversion and storage. The journal is devoted to reports of new and original experimental and theoretical research of an applied nature that integrate knowledge in the areas of materials, engineering, physics, bioscience, and chemistry into important energy applications.
期刊最新文献
Red ginseng polysaccharide promotes ferroptosis in gastric cancer cells by inhibiting PI3K/Akt pathway through down-regulation of AQP3. Diagnostic value of 18F-PSMA-1007 PET/CT for predicting the pathological grade of prostate cancer. Correction. Wilms' tumor 1 -targeting cancer vaccine: Recent advancements and future perspectives. Toll-like receptor agonists as cancer vaccine adjuvants.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1